A shot in the arm for new antibiotics
Document Type
Article
Publication Date
10-2019
ISSN
1546-1696
Publisher
Springer Nature
Language
en-US
Abstract
To the Editor — On 1 October, a new US Centers for Medicare and Medicaid Services (CMS) rule comes into effect that enhances economic incentives for newer antibiotics administered in US hospitals. The rule represents an economically significant post-approval (‘pull’) incentive to boost antibiotic development. If it is followed by further regulatory action in the coming year, it may prove to be the largest antibiotic pull incentive ever created by the US government. Although the new rule is a welcome shot in the arm for antibiotic discovery and development, the current moribund state of the antibacterial R&D ecosystem means that other incentives, such as a ‘market entry reward’, are still needed to fully incentivize drug companies to embrace (rather than leave) this space
Recommended Citation
Kevin Outterson,
A shot in the arm for new antibiotics
,
in
37
Nature Biotechnology
1110
(2019).
Available at:
https://scholarship.law.bu.edu/faculty_scholarship/3441
